Combivir contains the following FDA Boxed Warnings: Hematologic toxicity such as neutropenia and anemia can occur with the use of zidovudine, an active ingredient in Combivir. Prolonged use of zidovudine can cause symptomatic myopathy. Lactic acidosis and severe liver enlargement with steatosis can occur with the use of Combivir. Worsening hepatitis B can occur in patients with hepatitis B and HIV-1 and have stopped taking lamivudine, an active ingredient in Combivir. Liver function should be closely monitored in these patients and anti-hepatitis B treatment started if needed. Before you start treatment with Combivir, tell your doctor about:, All the prescription and nonprescription medications you take., Your allergies., Your health problems and past medical history., Your pregnancy or breastfeeding status., Do not take Combivir with other medications that contain lamivudine, zidovudine, or emtricitabine., Liver problems can occur in patients with HIV-1 and hepatitis C virus (HCV) who are receiving combination antiretroviral therapy and interferon alfa with or without ribavirin., Worsening anemia may occur in HIV-1 patients with HCV when taking ribavirin with zidovudine; therefore, this drug combination should be avoided in these patients., Pancreatitis can occur with the use of Combivir., Immune system disorders can occur with the use of Combivir., Accumulation of body fat can occur with the use of Combivir. All the prescription and nonprescription medications you take., Your allergies., Your health problems and past medical history., Your pregnancy or breastfeeding status.
